Many of the signaling responses induced by transforming growth factor-b (TGF-b) are mediated by Smad proteins, but there is evidence that it can also signal independently of Smads. Here, we provide evidence that multiple signal pathways induced by TGF-b1-including Src family tyrosine kinases (SFKs), generation of reactive oxygen species (ROS), de novo protein synthesis and E-cadherindependent cell-cell interactions-transactivate the epidermal growth factor receptor (EGFR), which in turn regulates expression of c-Fos and c-Jun. Immunoprecipitation and immunofluorescence staining showed that EGFR was phosphorylated on tyrosine in response to TGF-b1. EGFR transactivation required the activation of SFKs and the production of ROS via NADPH oxidase, but was not dependent on metalloproteases or the release of EGF-like ligands. In addition, the production of ROS was dependent on signaling by specific SFKs as well as de novo protein synthesis. Stable transfection of E-cadherin into MDA-MB-231 cells as well as E-cadherin-blocking assays revealed that E-cadherin-mediated cell-cell interactions were also essential for EGFR transactivation. Finally, EGFR transactivation was involved in the expression of c-Fos and c-Jun via the extracellular signal-regulated kinase signaling cascade. Taken together our data suggest that ligand release-independent transactivation of EGFR may diversify early TGF-b signaling and represent a novel pathway leading to TGF-b-mediated gene expression.
Introduction
Transforming growth factor-b (TGF-b) controls a wide range of physiological and pathological processes, including differentiation, immune responses, inflammation, extracellular matrix synthesis, angiogenesis and wound healing. Signaling by TGF-b family of growth factors is mediated by a heteromeric complex of two types of transmembrane serine/threonine kinase receptors. Binding of ligand to the receptor complex leads the type II receptor kinase to phosphorylate and thereby activate the type I receptor kinase. The activated type I receptor then phosphorylates receptor-activated Smads (R-Smads), for example, Smad2 and Smad3 proteins in the TGF-b pathway, or Smad1, Smad5 or Smad8 in the BMP pathway. After phosphorylation by the type I receptor kinase, the R-Smads bind to the related factor Smad4 and move to the nucleus. In the nucleus, this Smad complex associates with other transcription factors to regulate transcription of target genes (Massague, 2000; Derynck and Zhang, 2003) .
There is also evidence that TGF-b can signal through other pathways (non-canonical pathways). In one of the non-canonical pathways, it activates several mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs) and p38 (Hartsough and Mulder, 1995; Hocevar et al., 1999; Bhowmick et al., 2001) . Its effects on JNK, p38 and ERK MAPKs vary in kinetics and magnitude. In some cases, these kinases are activated with slow kinetics, indicating that activation occurs indirectly, possibly involving a Smad-dependent transcriptional response. For example, TGF-b-induced p38 activation requires the Smad-dependent expression of GADD45b in epithelial cells (Takekawa et al., 2002) . In other cases, however, activation is very rapid, suggesting that it is due to post-translational modification.
Several evidences have demonstrated that ERK activation is required for TGF-b responses such as actin rearrangement, growth inhibition, and induction of gene expression (Zavadil et al., 2001) , and it is probably that the oncogenic effects of ERK depend on activation of transcription factors. Among the transcription factors responsive to ERK signaling, the transcription factor AP-1, composed of Fos-Jun dimers, mediates many of the oncogenic changes that arise through changes in gene expression (Shaulian and Karin, 2002) . In mammary epithelial cells, persistent expression of c-Fos is associated with depolarization and acquisition of an invasive phenotype, a process generally referred to as an epithelial to mesenchymal transition (EMT) (Reichmann et al., 1992) . Activation of c-Fos causes the loss of the tumor-suppressive cell adhesion molecule E-cadherin from mammary epithelial cells, that is accompanied by cytoplasmic dispersion and nuclear translocation of the transcription factor b-catenin/lymphoid enhancerbinding factor, a component of the Wnt signaling pathway (Eger et al., 2000) . In addition, overexpression of c-Jun in these mammary epithelial cells results in epithelial disorganization without changes in invasive growth (Fialka et al., 1996) .
The mechanism of epidermal growth factor receptor (EGFR) transactivation has been mainly studied with G-protein-coupled receptor (GPCR) agonists (Wetzker and Bohmer, 2003) . A widely accepted mechanism involves triple-membrane-passing signaling (TMPS) mediated by intracellular stimulation of metalloproteinases (MMPs) or a-disintegrin-and-a-metalloproteinase (ADAMs), followed by shedding of EGF-like ligands, such as heparin-binding-epidermal growth factor (HB-EGF), TGF-a and amphiregulin. These in turn would activate the EGFR and the mitogenic cascade. However, many EGF-like ligand precursors are biologically active even when tethered to the plasma membrane, and so may be able to function as juxtacrine factors. They can induce tyrosine phosphorylation of EGFR expressed on juxtaposed cells without the release of detectable ligand, and are involved in cell-cell interactions (Iwamoto and Mekada, 2000; Singh and Harris, 2005) . Additional pathways of EGFR transactivation that do not involve MMP-mediated release of EGF-like ligands have also been identified. For example, Src family tyrosine kinases (SFKs) have been proposed to mediate EGFR activation downstream of GPCR (Luttrell et al., 1997) , and c-Src has even been shown to directly phosphorylate and activate EGFR (Biscardi et al., 1999) . Another possible mechanism that could affect the activity of EGFR is inactivation of protein-tyrosine phosphatases (PTPs). PTPs control the activity and signaling of receptor tyrosine kinases (Ostman and Bohmer, 2001) . It is also believed that transient and reversible PTP inactivation is involved in receptor tyrosine kinase signal generation. H 2 O 2 and other reactive oxygen species (ROS) inactivate PTPs by oxidizing the catalytic cysteine in their active sites (Rhee et al., 2000) . In addition to GPCR, EGFR is activated by cell adhesion molecules, growth factor receptors and stress agents (Zwick et al., 1999) . Among these, TGF-b is able to activate EGFR via shedding of HB-EGF and activation of MMPs, stimulating cell migration, and cell division (Uchiyama-Tanaka et al., 2002; Murillo et al., 2005; Samarakoon et al., 2005) . However, the mechanism responsible for EGFR transactivation in TGF-b signaling remains unclear.
In this report, we demonstrate that, in human keratinocyte (HaCaT) cells, TGF-b1 stimulates EGFR transactivation in a relatively delayed manner via complex pathways that are dependent on signaling by SFKs, ROS production and de novo protein synthesis, but not on shedding of EGF-like ligands such as HB-EGF and TGF-a. EGFR transactivation then induces c-Fos/c-Jun expression via the ERK signaling cascade. E-cadherin-mediated cell-cell interactions are also required for this event, similar with the effect of TGF-b on c-Src activation in epithelial cells, previously reported by us (Kim and Joo, 2002) .
Results

Stimulation of EGFR transactivation by TGF-b1
We demonstrated previously that TGF-b induces rapid and transient activation of c-Src in HaCaT cells (Kim and Joo, 2002) , implicating increased tyrosine phosphorylation of multiple proteins. To investigate whether TGF-b1 induces tyrosine phosphorylation of multiple proteins in HaCaT cells, serum-starved cells were stimulated with 4 ng/ml of TGF-b1 for various periods, lysed and analysed by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with anti-phosphotyrosine monoclonal antibody (mAb) (PY20). As shown in Figure 1a , TGF-b1 induced tyrosine phosphorylation of multiple proteins in a time-dependent manner. To identify the TGF-b1-induced phosphorylation of a band 170 kDa (arrow), serum-starved HaCaT was stimulated with 4 ng/ml TGF-b1 for 45 min, and lysates were subjected to affinity purification using an anti-PY20/agarose conjugate. Bound protein samples were resolved by SDS-PAGE and Coomassie blue staining. As shown in Figure 1b , a 170 kDa band (arrow) was apparent in the lane from TGF-b1-treated cells. The 170 kDa band was excised and digested with trypsin. Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/ MS) was performed as described in Materials and methods, resulting in the identification of 170 kDa protein as the EGFR. To confirm the induction of EGFR phosphorylation by TGF-b1, cell extracts were immunoprecipitated with anti-EGFR antibody, and the immunoprecipitates were analysed by SDS-PAGE followed by immunoblotting with PY20. Increased in tyrosine phosphorylation of EGFR was evident after 20 min, reaching a maximum after 45 min. Subsequently, tyrosine phosphorylation of EGFR declined gradually to almost baseline levels ( Figure 1c) . To confirm the specificity of the EGFR immunoprecipitation, we used a soluble EGFR fusion protein (glutathione S-transferase (GST) fused with the N-terminus of human EGFR), as a competitive inhibitor. As shown in Figure 1d , EGFR antibody effectively captured the soluble EGFR fusion protein (left panel, Coomassie blue staining), so decreasing the amount of cellular EGFR immunoprecipitated (right panel). In addition, immunoprecipitation ( Figure 1e , left panel) and immunofluorescence staining (Figure 1e , right panel) with specific antibodies for phospho-EGFR revealed that TGF-b1 mainly induced the phosphorylation of Tyr-845 of EGFR; phosphorylation of other sites (Tyr-992, Tyr-1045 and Tyr-1173) could not be detected with other phospho-EGFR antibodies.
Transactivation of EGFR by TGF-b1 is mediated by SFKs and requires de novo protein synthesis, but not by shedding of EGF-like ligands EGFR transactivation by other stimuli is commonly the result of shedding of EGF-like ligands processed by MMPs, activated SFKs and/or inhibition of phosphatases by oxidative stress (Wetzker and Bohmer, 2003) . To examine which of these processes is involved in TGF-b-induced EGFR transactivation in HaCaT cells, serum-starved cells were pretreated with neutralizing antibodies and specific chemical inhibitors, and subsequently stimulated with 4 ng/ml TGF-b1 for Figure 1 TGF-b1 stimulates EGFR transactivation. Serum-starved HaCaT cells were treated at 371C with 4 ng/ml TGF-b1 for various times (a-c), as indicated and subsequently lysed. (a) Tyrosine phosphorylation of total lysates (TL) was analysed by western blotting with anti-phosphotyrosine antibody (PY20). Serum-starved cells were incubated in the absence or presence of TGF-b1 for 45 min, lysed and then subjected to affinity purification (IP: PY20), using an anti-PY20/agarose conjugate. The samples were analysed by SDS-PAGE and Coomassie blue staining (CS). The 170-kDa protein band (arrow) was excised and analysed by LC-MS/MS as described in Materials and methods, resulting in identification of the protein as EGFR. (b) Total EGFR served as a loading control (WB: EGFR). (c) EGFR was immunoprecipitated (IP: EGFR) and detected for tyrosine phosphorylation by western blotting with anti-PY20. GST (GST) and GST-fused EGFR N-terminal protein (E-N) were added in equal amounts of cell lysates (TL) (EGFR, as a control), followed by EGFR immunoprecipitation. EGFR fusion protein captured by anti-EGFR (IP) was detected by Coomassie blue staining (CS). (d) C, EGFR fusion protein loaded as a control. After EGFR immunoprecipitation, western blotting was performed using phospho-specific EGFR antibodies (pEGFR-845, 992, 1045 and 1173) (e, left panel) . In addition, serum-starved cells grown in chamber slides were stained for phospho-EGFR (Tyr-845) (pEGFR-845) and EGFR (as a control) in the absence (CTRL) or in the presence of TGF-b1 (4 ng/ml for 45 min). Scale bars ¼ 50 mm (e, right panel). The results shown are representative of two or three independent experiments. DMSO, dimethyl sulfoxide; EGFR, epidermal growth factor receptor; GST, glutathione S-transferase; LC-MS/MS, liquid chromatography-mass spectrometry/mass spectrometry; SDS-PAGE, sodium dodecylsulfate polyacrylamide gel electrophoresis; TGF-b1, transforming growth factor-b1. 45 min. Treatment with PP2 and SU6656, specific inhibitors of SFKs, completely blocked EGFR transactivation (Figure 2a ). In contrast, pretreatment for 1 h with neutralizing antibodies to EGF-like ligands (a-HB-EGF and a-TGF-a), or with a broad-specificity MMP inhibitor (GM6001) that inhibits most MMPs and ADAMs by interfering with an essential Zn 2 þ binding motif in their catalytic domains (Levy et al., 1998; Takeda et al., 2006) , was without effect (Figures 2b and  c) . This confirms that the neutralizing antibodies and GM6001 were effective in our system (Figure 2d ). We also verified the effectiveness of the EGF neutralizing antibody and found that it did not block TGF-b1-induced EGFR transactivation (data not shown). However, cycloheximide completely inhibited transactivation (Figure 2c) . Because of the possibility that the expression of EGF-like ligands was induced by TGF-b (Vinals and Pouyssegur, 2001) , we examined the release of ligands, such as EGF, HB-EGF, TGF-a and amphiregulin, using enzyme-linked immunosorbent assays (ELISAs) to detect soluble forms ( Figure 2e , upper panel) as well as their inductions using western blotting in total cell lysates ( Figure 2e , lower panel) and reverse transcriptase (RT)-PCR (data not shown). In contrast to 24-h treatment, we did not detect any increased release of soluble EGF-like ligands or their induction by 45 min treatment. Western blot data for EGF and amphiregulin are not shown because these proteins were not detected. Interestingly, pretreatment for 1 h with a neutralizing antibody to EGFR (mAb LA1) blocked the EGFR transactivation by TGF-b1 (Figure 2f ). It is known that several neutralizing antibodies against EGFR, in addition to directly inhibiting the binding of soluble EGF-like ligands (autocrine/paracrine), can also influence the stability of monomeric EGFR, interact with EGFR (forming an alternative dimer that is then degraded) or block its association with other transmembrane proteins, including a juxtacrine interaction with membrane-anchored EGF-like ligand precursors in juxtaposed cells (Fan et al., 1994; Yu et al., 2002; Ferguson, 2004) . Hence this event may require architectural and structural functions of EGFR, such as association with other molecules, or the attainment of some special EGFR conformation, although further study will be needed to test this. Taken together, these findings indicate that multiple elements, including SFKs and de novo protein synthesis, regulate TGF-b1-induced EGFR transactivation in HaCaT cells, independent of shedding or induction of EGF-like ligands.
Transactivation of EGFR by TGF-b1 is responsible for activation of ERK The previous report demonstrated that TGF-b activates ERK in a slightly delayed manner (peaking at 45-60 min after TGF-b treatment) in HaCaT cells (Zavadil et al., 2001) , and this is confirmed by our data in Figure 3a .
Since the kinetics of ERK activation resembled those of EGFR transactivation by TGF-b1, we tested whether ERK activation by TGF-b1 could be mediated by EGFR. The results shown in Figure 3b indicate that TGF-b1-induced ERK activation was completely inhibited by AG1478 but not AG1295, a specific inhibitor of the platelet-derived growth factor receptor. In addition, AG1478 did not inhibit Smad2 phosphorylation by TGF-b1. These results show that the delayed TGF-b1-induced ERK activation is mediated by EGFR signaling.
Since we had shown that EGFR transactivation induced by TGF-b1 required SFK signaling and de novo protein synthesis, but was independent of the shedding or induction of EGF-like ligands, we examined whether these signaling events were also required for ERK activation by TGF-b1. Under conditions illustrated in Figure 2 , pretreatment with SFK inhibitors (Figure 3c ) and inhibition of de novo protein synthesis ( Figure 3e ) completely blocked ERK activation in response to TGF-b1. In contrast, pretreatment for 1 h with a-HB-EGF, a-TGF-a and GM6001 did not affect TGF-b1-induced ERK activation (Figures 3d and e). In parallel with EGFR transactivation (Figure 2f ), the neutralizing antibody to EGFR also blocked TGF-b1-induced ERK activation ( Figure 3f ). In addition, to confirm the role of SFKs as upstream mediators of EGFR transactivation, we examined whether EGFinduced ERK activation is involved in SFK signaling. ERK activation could be detected 2 min after treatment with 1 ng/ml EGF, reaching a maximum after 5-7 min (data not shown). As shown in Figure 3f , pretreatment with PP2 did not inhibit EGF-induced ERK activation, implying that it is independent of SFK signaling. Taken together, these findings indicate that TGF-b induces ERK activation in a delayed manner in HaCaT, by sequential activation of SFKs and EGFR.
The role of ROS in EGFR transactivation TGF-b has been shown to induce the production of ROS including the superoxide anion and H 2 O 2 , which may participate in TGF-b signal transduction as second messengers (Ohba et al., 1994; Thannickal and Fanburg, 1995) . Furthermore, ROS have been suggested to be potential mediators of transactivation of receptor tyrosine kinases by reversibly inhibiting PTPs (Rhee et al., 2000) . Therefore, we first asked whether ROSs are involved in the activation of EGFR and ERK by TGF-b1. As shown in Figure 4 , both diphenylene iodonium (DPI), an inhibitor of the enzyme NADPH oxidase that produces ROS, and N-acetyl cysteine (NAC), a broad range scavenger of ROS, strongly inhibited EGFR transactivation ( Figure 4a ) and ERK activation ( Figure 4b ).
Next, we examined the generation of ROS and its regulation in response to TGF-b1. Generation of ROS was measured over time in HaCaT cells treated with control or TGF-b1, by the incubation with 10 mM carboxymethyl-H 2 -dichlorofluorescein diacetate (CM-H 2 DCFDA) before the addition of TGF-b1. As shown in the confocal microscopy analysis of Figure 5a , we observed ROS generation in response to TGF-b1, peaking at 45 min. The preceding data showed that TGF-b-induced EGFR transactivation is regulated by SFKs and de novo protein synthesis in addition to oxidative stress. We therefore tested whether SFKs and de novo protein synthesis were involved in the ROS generation. Serum-starved HaCaT cells were exposed to PP2, SU6656 and cycloheximide, together with 10 mM CM-H 2 DCFDA, followed by treatment with TGF-b1 for another 45 min (Figure 5b ). Consistent with results for EGFR transactivation, cycloheximide and SU6656 completely blocked TGF-b-induced ROS generation, but interestingly, another SFK inhibitor, PP2, did not. It has been shown previously that the specificity of SU6656 for SFKs differs from that of PP2 (Davies et al., 2000; Bain et al., 2003) . Therefore, it appears that TGF-binduced ROS generation is regulated by a specifically Figure 2 Transactivation of EGFR by TGF-b1 is mediated by Src family tyrosine kinases (SFKs) and de novo protein synthesis, but independent of shedding or expression of EGF-like ligands. Serum-starved HaCaT cells were pretreated with SU6656 (SU), PP2 (PP2), GM6001 (GM), cycloheximide (CHX) and neutralizing antibodies for HB-EGF (a-HB) and TGF-a (a-T-a). Pretreated cells were then stimulated for 45 min without (À) or with ( þ ) 4 ng/ml TGF-b1, and subsequently lysed, immunoprecipitated with anti-EGFR and analysed with anti-PY20. EGFR transactivation by TGF-b1 was inhibited by specific inhibitors of SFKs, SU6656 and PP2 (a), but independent of shedding of EGF-like ligands, HB-EGF (b) and TGF-a (c), activated by MMPs or ADAMs (b). EGFR transactivation also requires de novo protein synthesis (c). To measure the effectiveness of neutralizing antibodies in our system, serum-starved HaCaT cells were pretreated with neutralizing antibodies of TGF-a (a-T-a) and HB-EGF (a-HB) for 30 min, and were then stimulated for 10 min without (À) or with ( þ ) 3 ng/ml TGF-a and 1 ng/ml HB-EGF, respectively (d, upper panel) . In addition, TGF-b1 and TPAinduced MMP-2 activations were completely inhibited by 10 mM GM6001 in HT1080 cells (d, lower panel) . To examine the levels of EGF-like ligands in serum-starved HaCaT cells treated for 45 min and 24 h with TGF-b1, cell supernatants were then analysed using ELISA (e, upper panel) and cell lysates by western blotting with anti-HB-EGF, anti-TGF-a and anti-actin (actin, as a control) (e, lower panel). Of interest, a neutralizing antibody of EGFR, unlike them of TGF-a and HB-EGF, effectively inhibited EGFR phosphorylation induced by both TGF-b1 (T) and HB-EGF (HB) (f). Shown are the means7s.d. of triplicates from a representative experiment (e, upper panel). The results shown are typical of those obtained in three independent experiments. ADAM, a disintegrin and a metalloproteinase; EGFR, epidermal growth factor receptor; ELISA, enzyme-linked immunosorbent assay; HB-EGF, heparinbinding-epidermal growth factor; MMP, metalloproteinase; TGF-b1, transforming growth factor-b1.
SU6656-sensitive SFK as well as by de novo protein synthesis. However, the pretreatment of GM6001 and neutralizing antibodies of HB-EGF and TGF-a did not effect ROS generation, parallel with TGF-b1-induced EGFR/ERK activation (data not shown).
Plasma membrane-associated NADPH oxidases are considered to be the main source of acute ROS production in response to growth factors and cytokines (Finkel, 2003) . In the event, TGF-b-induced ROS production was completely blocked by DPI, a potent inhibitor of NADPH oxidase (Figure 5c ). Furthermore, TGF-b1 activated NADPH oxidase in a time-dependent manner, peaking at 45 min ( Figure 5d ) and a SU6656-sensitive SFK as well as de novo protein synthesis were also involved in this activation (Figure 5e ), consistent with the data on ROS generation. E-cadherin expression and cell-cell interactions mediated by it are also essential for activation of EGFR/ERK signaling E-cadherin is a calcium-dependent cell interaction molecule that mediates homophilic interactions between many types of epithelial cells and is essential for tissue morphogenesis. Cell-cell interactions via E-cadherin involve extracellular binding and intracellular anchorage to the actin-based cytoskeleton (Takeichi, 1991) . Moreover, we showed previously that E-cadherin expression and cell-cell interaction mediated by it are important for TGF-b-induced c-Src activation (Kim and Joo, 2002) . Hence, we investigated the effects of E-cadherin expression and cell-cell interactions mediated by it on EGFR transactivation. However, we first needed to establish a novel mesenchymal to epithelial Figure 3 Transactivation of EGFR is responsible for activation of ERK. (a) Serum-starved HaCaT cells were exposed to TGF-b1 for the time periods indicated, and then analysed for ERK and Smad2 activation, using western blotting with anti-phospho-ERK (p-ERK1/2), anti-ERK (ERK1/2, as a control), anti-phospho-Smad2 (p-Smad2) and anti-Smad2/3 (Smad2/3, as a control). (b) Serumstarved cells were pretreated with AG1478 and AG1295 for 1 h and were then stimulated without (À) or with ( þ ) TGF-b1 for 45 min. ERK activation was specifically dependent on EGFR signaling, but not that of PDGF. (c-f) To confirm that EGFR transactivation is responsible for activation of ERK, cells were pretreated with several inhibitors or neutralizing antibodies and were then stimulated with TGF-b1, as described in Figure 2 . (g) Serum-starved cells were pretreated with 8 mM PP2 for 20 min, followed by EGF treatment (EGF, 5 min, 1 ng/ml). The cell lysates were processed for western blotting, as mentioned in (b). Shown are representative of two or three independent experiments. EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; PDGF, plateletderived growth factor; TGF-b1, transforming growth factor-b1.
transition (MET) model using human cell lines, because the antibody to human EGFR did not work with the L or L929 mouse cells used previously. We therefore used the procedure described in previous reports (Chen et al., 1997) , to establish a novel MET model using human MDA-MB-231 cells, which are E-cadherin-deficient (Chen et al., 2001) . MDA-MB-231 cells were stably transfected with pcDNA3 encoding human E-cadherin or a control plasmid and examined to see if they adopted an epithelial appearance as well as for expression of E-cadherin by western blotting. Individual clonal cell lines were isolated from E-cadherin-expressing pools to determine the effects of different levels of E-cadherin expression on TGF-b-induced EGFR transactivation. Clones that expressed high levels of E-cadherin also formed more cell clusters (Figure 6a ), and activation of EGFR and ERK induced by TGF-b correlated with the level of E-cadherin expression (Figure 6b ) (compare clones 231-E3 and 231-E1). However, we could not rule out another possibility, namely that TGF-b1 was unable to activate further EGFR/ERK in E-cadherin-deficient cells because it was already fully activated. We therefore tested the response to EGF, which is expected to fully activate EGFR in both types of cell. As shown in Figure 6c , unlike TGF-b1, EGF strongly induced the activation of EGFR/ERK in Mock cells, and had a slight effect in 231-E3 cells. This is consistent with a previous report that E-cadherin expression in MDA-MB-231 cells attenuates EGFR activation by EGF (Qian et al., 2004) . All MDA-MB-231 cell lines were responsive to Smad2 activation induced by TGF-b1. We also confirmed that SFK activation by TGF-b1 was dependent on the level of E-cadherin expression, as already observed with the L and L929 cells. As shown in Figure 6d , SFKs were activated by TGF-b1 in the E-cadherin-expressing 231-E3 cells, but not in the E-cadherin-deficient cells.
Interestingly, E-cadherin expression was also important for ROS generation (Figure 6e , upper panels) and NADPH oxidase activation (Figure 6e, lower panel) by TGF-b1, which appeared to be regulated by a SU6656-sensitive but not a PP2-sensitive SFK (Figure 6f) . Furthermore, SFK signaling and ROS were also involved in TGF-b-induced EGFR and ERK activation in the 231-E3 clones (Figure 6g) .
To confirm the role of E-cadherin-mediated cell-cell interactions in the activation of EGFR and ERK by TGF-b1, we utilized an E-cadherin blocking assay as described previously (Kim and Joo, 2002) . Briefly, HaCaT cells were pretreated for 18 h with HECD-1, an antibody against an epitope on the extracellular domain of E-cadherin; this resulted in dispersal of the E-cadherin over the cell surface and disruption of actin cytoskeletal networks. Under these conditions, EGFR and ERK were not activated by TGF-b1 (Figure 6h) . Evidently E-cadherin expression and E-cadherin-mediated cell-cell interactions are essential for activation of EGFR and ERK by TGF-b1.
EGFR transactivation is important for expression of c-Fos and c-Jun
Finally, to examine whether EGFR transactivation is involved in the regulation of gene expression by TGFb1, we screened AG1478-sensitive genes. Expression of c-Fos and c-Jun turned out to be strongly inhibited by AG1478, whereas that of GADD45b was not (Figure 7a ). We therefore asked whether the induction of c-Fos and c-Jun by TGF-b1 was dependent on SFKs, ROS and E-cadherin-mediated cell-cell interactions. As expected, the induction of c-Fos and c-Jun, but not GADD45b, was efficiently blocked by the SFK inhibitors SU6656 and PP2 (Figure 7b ) and was also affected by inhibiting ROS generation using DPI and by blocking E-cadherin-mediated cell-cell interactions with HECD-1 antibody (Figure 7c ). However, induction was independent of the shedding of EGF-like ligands or the activation of MMPs (Figure 7d ). Finally, we examined the role of MAPKs in induction of c-Fos and c-Jun. As shown in Figure 7e , their inductions were effectively blocked by an inhibitor of MEK (U0126), but not by inhibitors of JNK (SP600125) or p38 (SB203580). Taken together, these data suggest that the induction of c-Fos and c-Jun by TGF-b1 is mediated by complex signaling pathways, requiring E-cadherin-mediated cell-cell interactions, SFKs, ROS production and EGFR/ERK activation. The cell lysates were electrophoresed and immunoblotted with anti-phospho-ERK (p-ERK1/2) and anti-ERK (ERK1/2, to assure equal loading). Shown are typical of those obtained in three independent experiments. DPI, diphenylene iodonium; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; NAC, N-acetyl cysteine; ROS, reactive oxygen species; TGF-b1, transforming growth factor-b1.
in mesangial cells (Uchiyama-Tanaka et al., 2002) , regulation of the cell cycle in fetal rat hepatocytes (Murillo et al., 2005) and migration of smooth muscle cells (Samarakoon et al., 2005) . In that work, it was shown that TGF-b-induced EGFR transactivation was mediated by the shedding of EGF-like ligands, in a process known as TMPS (Wetzker and Bohmer, 2003) . Although TMPS is frequently responsible for EGFR transactivation, there is evidence for alternative pathways, such as transactivation mediated by SFKs (Luttrell et al., 1997) and oxidative stress (Frank et al., 2001 ). The results presented here demonstrate that in HaCaT cells, TGF-b stimulates EGFR transactivation via complex pathways that are dependent on SFK signaling, ROS production and de novo protein synthesis, but not on the shedding of EGF-like ligands such as HB-EGF and TGF-a.
In addition to activating Smad proteins, TGF-b activates the ERK pathway depending on cell type (Mulder, 2000; Zavadil et al., 2004) . Here, we showed that the delayed activation of ERK induced by TGF-b in HaCaT cells is mediated by EGFR transactivation, and also requires de novo protein synthesis, as in the delayed activation of p38 by Figure 5 TGF-b1 induces ROS generation and activity of NADPH oxidase. (a-c) ROS generation by TGF-b1. Serum-starved cells on chamber slides were preincubated for 30 min at 371C with 10 mM CM-H 2 DCFDA alone (a) or together with indicated inhibitors (b and c) in M199 lacking phenol red. Cells were then treated with TGF-b1 for various times as indicated (a) and without (CTRL) or with TGF-b1 for a further 45 min (b and c). Fluorescence intensity was measured by confocal microscopy as mentioned in Materials and methods. The results in panels (a-c) are representative of two or three independent experiments. Scale bars ¼ 50 mm. (d and e) The activation of NADPH oxidase. NADPH-dependent superoxide production was measured in the presence of 250 mM NADPH by lucigenin-derived chemiluminescence, as described in Materials and methods. Serum-starved cells were treated at 371C with TGF-b1 for various times as indicated (d) or pretreated with indicated inhibitors, followed by TGF-b1 treatment for a further 45 min (e). The NADPH oxidase activity is expressed as the ratio of specific enzyme activity (mean light units/min/mg protein) divided by control activity in the absence of TGF-b1 and inhibitors (mean light units/min/mg protein). Shown are the means7s.d. of triplicates from a representative experiment. *Po0.05 compared with TGF-b-induced oxidase activity in the absence of inhibitors. CM-H 2 DCFDA, carboxymethyl-H 2 -dichlorofluorescein diacetate; ROS, reactive oxygen species; TGF-b1, transforming growth factor-b1.
TGF-b via Smad-dependent GADD45b expression (Takekawa et al., 2002) . Although we do not know what proteins are rapidly induced by TGF-b1 and are responsible for the EGFR transactivation, some candidates can be suggested. One candidate is an EGF-like ligand that could directly activate EGFR. However, we detected no induction of EGF-like ligands such as EGF, HB-EGF, TGF-a and amphiregulin by western blotting, ELISA and RT-PCR, and blocking assays using their neutralizing antibodies revealed no role of EGFR/ERK activation. Another candidate is a protein regulating ROS production since TGF-b1-induced ROS production was inhibited by cycloheximide (Figure 5b) . We found that TGF-b-induced ROS generation was Figure 6 E-cadherin-mediated cell-cell interactions are essential for activation of EGFR/ERK signaling. (a) Stably transfected MDA-MB-231 clones with empty vector (Mock) or pcDNA3-human E-cadherin (231-E1 and 231-E3) were plated on culture dishes and chamber slides for 24 h. Subconfluent cells cultured on culture dishes were washed, fixed and then visualized with light microscopy, following toluidine blue staining. (b) EGFR and ERK activation induced by TGF-b in E-cadherin expressed MDA-MB-231 cells. Serum-starved Mock, 231-E1 and 231-E3 clones were treated in the absence (À) or in the presence ( þ ) of 10 ng/ml TGF-b for 45 min and lysed. Half of immunoprecipitates with EGFR (IP: EGFR) was processed for western blotting with anti-PY20 and anti-EGFR and the other half (TL) was subject to western blotting with anti-E-cadherin (Ecad), anti-phospho-ERK (p-ERK1/2), anti-phospho-Smad2 (p-Smad2) and anti-Smad2/3 (Smad2/3, to confirm equal amounts of total loading protein). (c) To examine the possibility that TGF-b1 would be unable to activate further EGFR/ERK in Mock cells if they were already fully activated, both serum-starved cells (Mock and 231-E3) were treated without (À) or with (E) 1 ng/ml EGF for 10 min. (d) To examine whether E-cadherin expression is essential to SFK activation by TGF-b, Mock and 231-E3 clones were treated with 10 ng/ml TGF-b1 for the indicated times (left panel). To verify these results, both cells were stimulated without (À) or with ( þ ) TGF-b1 for 45 min (right panel). Cellular lysates were subject to western blotting with anti-phospho-Src (p-Src416) and anti-pan SFK (SRC2, as a control). (e) A role of E-cadherin expression in ROS generation (upper panel) and the activation of NADPH oxidase (lower panel). ROS generation and the activity of NADPH oxidase after TGF-b1 treatment for the indicated times were measured as described in Figures 5a and d. (f-g) To confirm a role of SFK, serum-starved 231-E3 cells were pretreated with SU6656 (SU), PP2 and DPI, and then treated without (À) or with ( þ ) TGF-b1 for a further 45 min. ROS production (f, upper panel), the activity of NADPH oxidase (f, lower panel) and EGFR/ERK activation (g) was analysed. (h) After pretreatment of 25 mg/ml normal mouse IgG (IgG) or HECD-1 (HECD-1) for 18 h, HaCaT cells were then treated in the absence (À) or in the presence ( þ ) of 4 ng/ml TGF-b for 45 min and EGFR/ERK activation was analysed. Scale bars in panels (a, e and f) represent 50 mm. Shown in e and f (lower panels) are the means7s.d. of triplicates from a representative experiment. *Po0.05 compared with TGF-b-induced NADPH oxidase activity in the absence of inhibitors. The results in panels (b-h) are representative of two or three independent experiments. EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; TGF-b1, transforming growth factor-b1. dramatically inhibited by DPI, suggesting the involvement of NADPH oxidase, consistent with the previous study (Chiu et al., 2001) . Furthermore, the activation of this enzyme also required de novo protein synthesis (Figure 5e ), implying that some component of this enzyme can be induced by TGF-b1 and control its activity. NADPH oxidase consists of two membranespanning subunits: p22phox, which is thought to serve as a stabilizing and regulatory subunit for gp91phox (Nox2) and the superoxide producing subunit and its homologues Nox1 and Nox4. The cytoplasmic components of the oxidase, p47phox and p67phox, as well as Rac (Rac1 or Rac2) are thought to regulate the assembly of the functional oxidase, and thus, also its activity (Rocic and Lucchesi, 2005) , and they are inducible (Carmona-Cuenca et al., 2005) . We therefore propose that activation of NADPH oxidase through de novo synthesis of a component of this enzyme may result in a delayed EGFR/ERK activation.
In the present study, SFKs also mediated TGF-binduced EGFR transactivation, which was inhibited by the SFK inhibitors PP2 and SU6656, and Tyr-845 of EGFR was found to be the major phosphorylation site. Interestingly, the activation of NADPH oxidase and ROS generation induced by TGF-b1 were sensitive to SU6656 but not PP2 (Figures 5b and e) . Considering that specificities of PP2 and SU6656 for SFKs are different (Davies et al., 2000; Bain et al., 2003) , these findings suggest the possibility of dual pathways of EGFR transactivation via distinct SFKs: a PP2-sensitive SFK may directly phosphorylate EGFR, while an SU6656-sensitive SFK indirectly phosphorylates EGFR via activation of NADPH oxidase. However, further study is required to identify the SFKs and newly Ligand release-independent EGFR transactivation by TGF-b1 C-K Joo et al synthesized proteins involved, and to elucidate the exact mechanism in EGFR transactivation and NADPH oxidase activation through SFKs induced by TGF-b1.
In addition, we previously showed that TGF-b1-induced c-Src activation in HaCaT cells required E-cadherin-mediated cell-cell interactions (Kim and Joo, 2002) . This prompted us to test whether EGFR transactivation and ROS generation required E-cadherin expression and the resulting cell-cell interactions. Stably E-cadherin-expressing MDA-MB-231 cells displayed similar effects to HaCaT by TGF-b1, correlating with the level of expressed E-cadherin, but E-cadherindeficient cells were observed to have no effect. In contrast with MDA-MB-231 cells, TGF-b has been previously reported to be capable of inducing ROS generation in some fibroblast cell lines in a relatively delayed manner (Thannickal and Fanburg, 1995; Cucoranu et al., 2005) , comparable to that in HaCaT and 231-E3 cells. The reason for the different kinetics of ROS generation remains unknown. However, because E-cadherin expression in non-polarized fibroblast cells changes the structure of the actin cytoskeleton and it directly or indirectly associates with other signal molecules including SFKs (Piedra et al., 2003) and EGFR (Pece and Gutkind, 2000) , it is conceivable that the ROS generating systems in E-cadherin-expressing cells differ from those in fibroblasts. Moreover, E-cadherin clustering influences the activities of various Total RNA samples were analysed by Northern blot analysis as described in Materials and methods. Ethidium bromide-stained gels of the same samples are shown to indicate the amount of RNA applied (total RNA). Gels were loaded with 10 mg of mRNA and Northern blotting was performed using specific PCR-amplified fragments as probes for c-Fos, c-Jun and GADD45b. The results shown are typical of those obtained in three independent experiments. U, U0126; SP, SP600125; SB, SB203580. EGFR, epidermal growth factor receptor; TGF-b1, transforming growth factor-b1. signal molecules including small GTPases Rac (Kovacs et al., 2002) , EGFR/ERK (Pece and Gutkind, 2000) and phosphatidylinositol 3-kinase (Kovacs et al., 2002) . Therefore, this leads us to suggest that the alteration of actin structure and the association with other signal molecules resulting from E-cadherin expression may generate a complex that activates other signal molecules such as SFKs, resulting in effective production of ROS.
In addition, EGFR also has an important role in cell-cell interactions via juxtacrine interaction with the precursors of EGF-like ligands (Iwamoto and Mekada, 2000; Singh and Harris, 2005 ) and can bind directly or indirectly to E-cadherin (Qian et al., 2004) . This, together with the effect of EGFR neutralizing antibody shown in Figure 2f , suggests that juxtacrine signaling plays a role in TGF-b1-induced EGFR transactivation as a part of the epithelial architecture.
TGF-b is a multifunctional cytokine that induces actin rearrangement, accumulation of extracellular matrix proteins, stimulates cell motility and regulates the cell cycle, at the same time controlling the transcription of specific sets of genes. To investigate the role of EGFR/ERK activation in TGF-b-induced gene expression, we screened immediate early genes induced by TGF-b1 in HaCaT cells (data not shown), looking for those whose expression was inhibited by AG1478. Among such genes, we identified c-Fos and c-Jun, the components of the AP-1 transcription factor, which are a potent inducer of EMT (Reichmann et al., 1992; Fialka et al., 1996) . Upregulation of c-Jun and c-Fos transcripts by TGF-b occurs in a wide range of cell lines derived from both normal and transformed cells (Pertovaara et al., 1989; Lafon et al., 1995) . These responses to TGF-b are early and immediate, with mRNA induced within 15-60 min. In present study, TGF-b transiently induced the expression of c-Fos and c-Jun within 45-60 min in HaCaT (data not shown).
In conclusion, TGF-b induces EGFR transactivation in HaCaT, which requires multiple signal pathways including E-cadherin-mediated cell-cell interactions, SFKs, ROS and de novo protein synthesis, but independent of shedding of EGF-like ligands. Furthermore, EGFR transactivation by TGF-b is involved in ERK activation, regulating both inductions of c-Fos and c-Jun. These findings provide a novel signal transduction of TGF-b linked to EGFR cellular signaling in a gene expression of epithelial cells. Further studies will be necessary to identify the SFKs and newly synthesized proteins involved, as well as to examine other roles of EGFR transactivation in TGF-b cellular responses, such as actin rearrangement, migration and cell-cycle regulation.
Materials and methods
Reagents TGF-b1, EGF, HB-EGF, TGF-a and neutralizing antibodies of EGF, amphiregulin, HB-EGF, and TGF-a were obtained from R&D System (Minneapolis, MN, USA). ELISA kits of EGF, amphiregulin and TGF-a were also from R&D System. Mouse anti-human EGFR neutralizing mAb, clone LA1, was from Millipore Co (Beverly, MA, USA). Fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG, horseradish peroxidaseconjugated anti-mouse and anti-rabbit IgG, normal mouse IgG, NAC, NADPH, toluidine blue, Lucigenin, anti-actin mAb, and bovine serum albumin (BSA) were from SigmaAldrich (St Louis, MO, USA). PP2, SU6656, AG1478, AG1295, DPI, GM6001, cycloheximide, U0126, SB203580 and SP600125 were from Merck Biosciences (Darmstadt, Germany). Pan-SFKs (SRC2), EGFR (1005), ERK (C-16), and phospho-EGFR (Tyr-1173) polyclonal antibodies (pAbs), protein G þ agarose and enhanced chemiluminescence reagent were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). E-cadherin (clone 36) and phosphotyrosine (PY20) mAbs were from BD Biosciences (San Jose, CA, USA). Polyclonal anti-phospho-Smad2 (Ser-465/ 467), anti-phospho-EGFR (Tyr-845, 992, and 1045) , and antiphospho-ERK (Thr-202/Tyr-204) pAbs, and anti-Smad2/3 mAbs were from Cell Signaling Technology (Denvers, MA, USA) EGFR mAb (Ab-13) for immunoprecipitation and recombinant human EGFR fusion protein encoding N-terminus were from Lab Vision Co (Fremont, CA, USA). Anti-human E-cadherin IgG (HECD-1) mAb, anti-phospho-Src (Tyr-416) pAb, CM-H 2 DCFDA, G418 and all culture reagents were purchased from Invitrogen (Carlsbad, CA, USA) and other reagents used were of the purest grade available.
Cell lines and establishment of stable E-cadherin-expressed MDA-MB-231 cells HaCaT, human fibrosarcoma HT1080 cells and human breast carcinoma cells (MDA-MB-231) were maintained in Dulbecco's modified Eagle's medium (DMEM with low glucose) supplemented with 10% fetal bovine serum (FBS) and 100 U/ ml penicillin and 100 mg/ml streptomycin at 371C in a humidified atmosphere of 5% CO 2 . For establishment of stable E-cadherin-expressed cells, transfections of pcDNA3-human E-cadherin (kindly gifted by Dr P Cossart (Institute of Pasteur, Paris, France) (Lecuit et al., 1999) and control vector pcDNA3 into MDA-MB-231 cells were performed using LipofectAMINE reagent (Invitrogen), according to the manufacturer's instructions. The transfected cells were selected in DMEM supplemented with 10% FBS in the presence of 400 mg/ml G418 in a humidified atmosphere comprising 5% CO 2 , 95% air at 371C for about 2 weeks. Then, the G418-resistant colonies were isolated, screened for cell clustering by light microscopy, following toluidine blue staining, and for E-cadherin expression by western blot using anti-mouse E-cadherin antibody (clone 36), as described below, and maintained under the above condition.
Cell stimulation and blocking the cell-cell interaction For TGF-b1 stimulation (4 ng/ml for HaCaT and 10 ng/ml for MDA-MB-231 clones), subconfluent cells were serum starved for 48 h in serum-free media containing 0.5% BSA. They were washed once with serum-free media, treated with TGF-b1 as indicated and then lysed as described below. In some experiments, serum-starved cells were pretreated with 8 mM PP2, 10 mM SU6656, 10 mM GM6001, 400 nM AG1478, 10 mM AG1295, 10 mg/ml cycloheximide, 5 mg/ml DPI, 20 mM NAC, 10 mM U0126, 5 mM SB203580, 10 mM SP600125 and 10 mg/ml neutralizing antibodies for HB-EGF and TGF-a, before TGF-b1 stimulation. To block cell-cell interaction, subconfluent HaCaT cells grown in DMEM containing 10% FBS were washed twice with serum-free media and then treated with 25 mg/ml HECD-1 or control mouse IgG for 18 h, followed by TGF-b1 stimulation.
Immunoprecipitation and western blotting
For western blotting analysis following immunoprecipitation using anti-EGFR, cells were washed twice with ice-cold phosphate-buffered saline (PBS), and then, lysed in (1 ml/100-mm plate) modified RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM EGTA (ethylene glycol bis(b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid), 1 mM dithiothreitol, 1.2 mM MgCl 2 , 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 10% glycerol, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 20 mM b-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 1 mg/ml leupeptin and 1 mg/ml pepstatin) on ice. For immunoprecipitation of EGFR, the lysate was centrifuged at 15 000 r.p.m. for 20 min and the supernatant was transferred to a new tube, and was incubated for overnight at 41C with EGFR mAb (Ab-13).
Immunoprecipitates were collected with protein G þ agarose for 2 h. Immunoprecipitated proteins and total lysates were resolved on an SDS-PAGE and then electrophoretically transferred to Nitrocellulose membranes. The membranes were blocked with 1% BSA and 10% skim milk in Trisbuffered saline containing 0.1% Tween 20 (TBST) for 1 h and were incubated for overnight at 41C with specific antibodies. Following washing with TBST, antibody binding was detected using peroxidase-conjugated goat anti-mouse IgG or antirabbit IgG and visualized with ECL reaction reagents.
Identification of proteins by LC-MS/MS
Serum-starved cells were stimulated with or without TGF-b1 (4 ng/ml for 45 min) and then lysed with modified RIPA buffer, and immunoprecipitated with anti-PY20/agarose conjugate. Samples were washed three times and analysed by SDS-PAGE and Coomassie blue staining. Protein bands of interest were excised and digested in-gel with sequencing grade, modified trypsin (Promega, Madison, WI, USA) as previously described (Bahk et al., 2004) . The resulting tryptic peptides were separated and analysed using reversed phase capillary highperformance liquid chromatography directly coupled to a Finnigan LCQ ion trap mass spectrometer (LC-MS/MS) (Zuo et al., 2001) . The individual spectra from MS/MS were processed using the TurboSEQUEST software (Thermo Quest, San Jose, CA, USA). The generated peak list files were used to query either MSDB database or NCBI using the MASCOT program (http://www.matrixscience.com).
Quantitative analysis of EGF-like ligands
The media of cultured HaCaT cells were analysed for the following soluble EGF-like ligands: EGF, amphiregulin, HB-EGF and TGF-a. EGF, amphiregulin and TGF-a were measured using commercially available ELISA kits according to the manufacturer's guidelines. ELISAs were also used to measure HB-EGF. Briefly, 50 ml of cultured media was incubated overnight with 50 ml of bicarbonate/carbonate buffer, pH 9.2, at 41C in a 96-well plate. Then plates were washed three times with 20 mM Tris, 500 mM NaCl, 0.05% Tween 20, pH 7.5 (TTBS) and blocked with 1% BSA in TTBS for 6 h at room temperature. After washing, plates were incubated with 100 ml of mouse monoclonal anti-HB-EGF antibody (R&D Systems, 10 mg/ml diluted into TTBS). After 2 h, the wells were washed, and 100 ml of goat anti-mouse IgG (0.2 mg/ml), conjugated to alkaline phosphatase, were dispensed into each well and incubated for 2 h. Color was developed with p-nitrophenyl phosphate and stopped with 3 N NaOH. Absorbance was read at 410 nm. EGF-like ligands concentrations were determined by interpolation from the standard curves.
Immunofluorescence staining
HaCaT cells were grown on Lab-Tek-chambered glass slides (Nunc, Roskilde, Denmark). After 24 h, cells grown in DMEM containing 10% FBS were serum-starved for 48 h in DMEM containing 0.5% BSA. Following 4 ng/ml TGF-b1 treatment for 45 min, cells were then fixed in freshly made 4% paraformaldehyde/PBS at room temperature for 15 min, incubated with 100 mM glycine in PBS for 20 min to block aldehydes, rinsed three times for 10 min in 0.5 mM glycine/PBS, permeabilized in 0.5% Triton X-100, 0.5 mM glycine/PBS for 10 min, rinsed three times for 10 min in 0.5 mM glycine/PBS and blocked in PBS containing 2% BSA for 1 h. For EGFR and phospho-EGFR staining, cells were incubated with anti-EGFR (1005) and anti-phospho-EGFR pAbs in blocking buffer for overnight at 41C. As secondary antibodies, FITCconjugated anti-rabbit and goat antibodies were used. Finally, cells were washed, mounted in anti-fade medium (Invitrogen) and examined by a conventional inverted fluorescence microscopy (Model S 100; Carl Zeiss Inc., Oberkochen, Germany) and captured images were processed by Adobe Photoshop.
Measurement of NADPH oxidase activity
Superoxide production was measured in total cell homogenates by using lucigenin-derived chemiluminescence (Rajagopalan et al., 1996; Sorescu et al., 2001) . Briefly, cells were treated as indicated, washed twice with ice-cold PBS and scraped from the dishes. After a step of low spin centrifugation (1000 Â g for 5 min), the pellet was re-suspened in ice-cold buffer (50 mM phosphate (pH 7.0), 1 mM EGTA, 150 mM sucrose and protease inhibitors as described above). Then, the cells were mechanically lysed, using a glass/Teflon potter on ice. The homogenate was subjected to low spin centrifugation (1000 Â g for 10 min) to remove unbroken cells and debris. The total protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA), adjusted to 1 mg/ml. After the addition of 20 mM lucigenin and 250 mM NADPH to the sample, background was recorded for 5 min and then chemiluminescence measurement was immediately started. Chemiluminescence was measured at 15-s intervals for 5 min in a Turner 20/20 luminometer (Turner Designs, Sunnyvale, CA, USA). No changes in luminescence were observed in the absence of NADPH, and addition of H 2 O 2 to lucigenin in PBS in the absence of cells did not increase chemiluminescence. Furthermore, we normalized the results of the NADPH oxidase assay using DPI. In some experiments, the homogenate was preincubated with various inhibitors, followed by TGF-b1 treatment.
Determination of intracellular ROS generation
Generation of intracellular ROS was measured with the fluoroprobe (CM-H 2 DCFDA; Invitrogen) (Hua et al., 2003) . CM-H 2 DCFDA is a nonpolar compound that is converted into a nonfluorescent polar derivative (CM-H 2 DCFDA) by cellular esterases after incorporation into cells. CM-H 2 DCFDA is rapidly oxidized to the fluorescent 2 0 ,7 0 -dichlorofluorescein in the presence of intracellular ROS. Briefly, subconfluent HaCaT and MDA-MB-231 clones were preincubated for 30 min at 371C with 10 mM CM-H 2 DCFDA (in some experiments, together with specific inhibitors) in M199 lacking phenol red, followed by TGF-b1 treatment for indicated. Fluorescence intensity was measured by confocal microscopy (Bio-Rad Laboratories; excitation 488 nm and emission 513 nm). To avoid photooxidation of 2 0 ,7 0 -dichlorofluorescein, the fluorescence image was collected by a single rapid scan (four-line average), with identical parameters such as contrast and brightness.
Gelatin zymography
To examine the effectiveness of GM6001 in HT1080 cells, we measured the inhibitory effect of 10 mM GM6001 on the activation of proMMP-2 induced by TGF-b1 or TPA, using gelatin zymography as described previously (Kleiner and Stetler-Stevenson, 1994) . Briefly, an equally concentrated aliquot (20 ml) of the culture medium was subjected to SDS-PAGE in a gel containing 0.1 mg/ml gelatin. The gels were then incubated in 2.5% Triton X-100 and rinsed in doubledistilled H 2 O. Gels were further incubated at 371C for 20 h in 20 mM NaCl, 5 mM CaCl 2 , 0.02% Brij-35, 50 mM Tris-HCl buffer, pH 7.6, and then stained with 0.1% Coomassie Brilliant Blue R-250 and destained in 10% acetic acid and 30% methanol in H 2 O. Gelatinolytic activity was detected as unstained bands on a blue background.
RNA isolation and Northern blotting
Total RNA was prepared by a TRIzol (Invitrogen) method and Northern blot analysis was performed as described previously (Park et al., 2001) . Total RNA (10 mg) was denatured and separated on a 1% formaldehyde-agarose gel in MOPs buffer containing 50 mM sodium acetate, MOPs, 2 N NaOH and 0.5 M EDTA (pH 8.0). The RNA was then transferred onto a Hybond-N þ nylon-membrane (S&S, Dassel, Germany). The membrane was prehybridized in Rapid-Hyb solution (BD Biosciences) at 681C for 2 h and then hybridized with radiolabeled cDNA probe at 681C for 24 h. cDNA probes for c-Fos, c-Jun and GADD45b were radiolabeled with [a-32 P] dCTP (6000 Ci/mmol; PerkinElmer, Waltham, MA, USA) with the use of a random primerlabeling kit (Roche, Penzberg, Germany). After washing twice in 2 Â SSC/0.01% SDS (Invitrogen) at 681C for 20 min, the membrane was exposed to X-ray film (Fujifilm Co., Tokyo, Japan) at À701C. mRNA levels were corrected for the levels of 18S and 28S rRNAs in the same samples.
Statistical analysis
Statistical analysis was performed using SigmaPlot. Results are presented as the mean7s.d. at least three different experiments for each condition. Unpaired Student's t-test and analysis of variance were performed as specified in Figures 5e and 6f (lower panel). A value of Po0.05 was considered to be statistically significant.
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